ALKS Q2 2020 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$248M-11.6% YoY

Gross Profit

$202M81.8% margin

Operating Income

-$34M-13.6% margin

Net Income

-$29M-11.9% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+0.5%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$15M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$740M

Stockholders' Equity

$1.1B

Cash & Equivalents

$189M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$248M	$280M	-11.6%
Gross Profit	$202M	$234M	-13.3%
Operating Income	-$34M	-$36M	+6.3%
Net Income	-$29M	-$42M	+29.9%

Revenue Segments

Product

$130M50%

Vivitrol

$72M27%

Aristada Or Aristada Initio

$59M23%